. Correlation between annual rates of resistance to ciprofloxacin in enterococci and Escherichia coli isolates and consumption of 3 fluoroquinolones (ciprofloxacin, levofloxacin, and moxifloxacin) from 2001 through 2003 at National Taiwan University Hospital. Isolates were recovered from patients treated in a hematology/oncology ward (A) and a bone marrow transplantation ward (B). DDD, defined daily dose.
(among antiretrovirals) possesses a rather large therapeutic index; (2) abacavir toxicity, particularly the hypersensitivity reaction, does not appear to be related to abacavir levels; and (3) if the administration of antiretrovirals to persons with hepatic impairment were limited to only those drugs for which adequate pharmacokinetic and safety data are available, many of the currently available antiretrovirals would be eliminated. If you combine these points with emerging data that suggest control of HIV infection may slow the progression of hepatitis C virus-related liver disease in coinfected individuals [4, 5] , these limitations could certainly adversely impact the survival and quality of life of persons with HIV and hepatitis C virus infections. In our letter [3] , we took a less dogmatic approach, stating that treatment with the drug should not be withheld if other compelling factors support the use of abacavir in the presence of more advanced hepatic dysfunction [3] .
Prophylactic Use of Moxifloxacin in Patients Receiving Bone Marrow Transplants Was Not Associated with Increased Ciprofloxacin Resistance in Escherichia coli and Enterococci
Sir-Quinolone use for antibacterial prophylaxis in patients with febrile neutropenia has become widespread since 1990, and use of fluoroquinolones, including norfloxacin, ciprofloxacin, and levofloxacin, has been associated with the emergence of quinolone-resistant Escherichia coli and viridans group streptococci [1] [2] [3] [4] . Moxifloxacin was introduced into National Taiwan University Hospital in 2002, and since 2003, this agent, instead of ciprofloxacin, has been extensively used (at a dosage of 400 mg q.d. for 14-21 days) for prophylaxis of infection for patients in the 6-bed bone marrow transplantation (BMT) ward at the hospital. During this time, fluoroquinolones were used only for therapeutic purposes in patients with febrile neutropenia in the 3-bed hematology/ oncology (HO) ward at the hospital. The present study found that, although there was widespread use of moxifloxacin among patients in the BMT ward, rates of ciprofloxacin resistance remained relatively stable in E. coli or decreased in enterococci. A possible explanation for this finding is that moxifloxacin, compared with ciprofloxacin and levofloxacin, has less potential for selection of antibioticresistant mutants because of favorable mutation protection concentration [5] . This study also demonstrated that increased use of fluoroquinolones in the HO ward was associated with increased ciprofloxacin resistance in E. coli and enterococci, although this correlation did not reach statistical significance for E. coli. This finding was in agreement with previous reports. However, the prevalence of quinolone-resistant bacteria at a hospital depends on several factors, such as the adequacy of infection control (to prevent clonal spreading of drug-resistant bacteria), the use of some unrelated antibiotics (to prevent cross-resistance to other antibiotics in quinolone-resistant isolates), the characteristics of patients, and pathogen-specific dynamics [1, 5] . Previous studies have demonstrated that a correlation between ciprofloxacin use and the development of drug resistance existed in E. coli and viridans group streptococci but not in Pseudomonas aeruginosa and staphylococci [1] . Our findings extend these findings to enterococci. Moxifloxacin has been shown to be a more efficient agent than ciprofloxacin in the prophylaxis of infection in patients with cancer who have neutropenia [6] . The observation of the low possibility of the development of ciprofloxacin resistance during prophylactic use of moxifloxacin favors its suitability to replace ciprofloxacin as a prophylactic agent in patients receiving a BMT. However, routine use of antibiotics for bacterial prophylaxis is not recommended for hematopoietic stem cell transplant (HSCT) candidates [7] . If physicians choose to use a single antibiotic for antibacterial prophylaxis among asymptomatic, afebrile, neutropenic transplant recipients, routine reviews of hospital and HSCT ward antibiotic-susceptibility profiles are necessary [7, 8] . In the interim, routine use of a fluoroquinolone as a prophylactic agent is not recommended in the BMT ward of National Taiwan University Hospital because of a high rate of fluoquinoloneresistant bacteria.
